MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2022 International Congress

    Adult-onset axial dystonia: a rare condition that can lean on an early combined treatment approach

    P. Mitrotti, G. Vaghi, V. Grillo, C. Susca, R. de Icco, M. Allena, M. Avenali, C. Tassorelli (Pavia, Italy)

    Objective: To describe a rare case of adult-onset axial dystonia treated successfully with a  combined therapeutic approach. Background: Adult-onset truncal dystonia is an unusual condition…
  • 2022 International Congress

    The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients

    O. Samotus, M. Jog (London, Canada)

    Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…
  • 2022 International Congress

    Task Specific Oromandibular dystonia due to Shisha (Hookah) Smoking- “Shisha Dystonia”

    S. Mittal, H. Yu, P. Krystkowiak (Abu Dhabi, United Arab Emirates)

    Objective: To report an unusual case of oromandibular dystonia due to repeated task of smoking shisha/hookah. Background: Focal task-specific dystonia is common in men, aged…
  • 2022 International Congress

    Short and long-term cental action of botulinum neurotoxin treatment in laryngeal dystonia

    L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To investigate short- and long-term central effects of BoNT treatment on brain function in patients with laryngeal dystonia (LD). Background: LD is an isolated…
  • 2022 International Congress

    Characteristics and Treatment Response to OnabotulinumtoxinA of Patients From CD-PROBE With Retrocollis Subtype of Cervical Dystonia

    K. Dashtipour, J. Jankovic, D. Charles, S. Mehta, M. Schwartz, M. Sadeghi (Loma Linda, USA)

    Objective: To describe characteristics and treatment response to onabotulinumtoxinA (onabotA) of patients with retrocollis (RC). Background: The CD-PROBE trial of onabotA included patients with RC,…
  • 2022 International Congress

    DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia

    D. Yao, L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…
  • 2022 International Congress

    Awake Bruxism, a case series of an underrecognized disorder

    I. Trigo, B. Solano Vila, D. Domínguez (Girona, Spain)

    Objective: We present a series of 3 cases with Awake Bruxism (AB) and frontal dysfunction. Background: AB is an infrequent, daytime form of bruxism, described…
  • 2022 International Congress

    Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

    Objective: We describe a case of pseudodystonia caused by palmaris brevis syndrome. Background: Palmaris brevis (PB) syndrome is a pseudodystonia characterized by spontaneous, involuntary, nonpainful…
  • 2022 International Congress

    Botulinum Toxin Outcomes in Patients with Lower Limb Dystonia

    M. Wajid, J. Frey, L. Kugler, T. Stiep, J. Yu, J. Toledo, J. Lopes, A. Ramirez-Zamora, A. Rawls, A. Wagle Shukla, I. Malaty (Gainesville, USA)

    Objective: To assess botulinum toxin outcomes in patients with lower limb dystonia. Background: One of the most effective treatments for dystonia is botulinum toxin (BoNT)…
  • 2022 International Congress

    Development of a patient journey map for people living with cervical dystonia

    M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner (Brussels, Belgium)

    Objective: As part of the ongoing European Reference Networks for Rare Neurological Diseases (ERN-RND) program, we aimed to develop a cervical dystonia patient journey map…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley